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Abstract: The Athens Insomnia Scale (AIS) can be regarded as a highly useful instrument in both
clinical and research settings, except for when assessing the severity level. This study aims to
determine the severity criteria for AIS by using the Insomnia Severity Index (ISI). A total of 1666
government employees aged 20 years or older were evaluated using the AIS and ISI, the Patient
Health Questionnaire for depressive symptoms, the Epworth Sleepiness Scale for daytime sleepiness,
and the Short Form Health Survey of the Medical Outcomes Study for health-related quality of
life (QoL). A significant positive correlation (r) was found between the AIS and the ISI (r = 0.80,
p < 0.001). As a result of describing receiver–operator curves, the severity criteria of the AIS are
capable of categorizing insomnia severity as follows: absence of insomnia (0–5), mild insomnia (6–9),
moderate insomnia (10–15), and severe insomnia (16–24). In addition, compared to all scales across
groups categorized by AIS or ISI, it was revealed that similar results could be obtained (all p < 0.05).
Therefore, the identification of the severity of AIS in this study is important in linking the findings of
epidemiological studies with those of clinical studies.
Keywords: Athens Insomnia Scale; Insomnia Severity Index; depression; quality of life; cutoff; sleepiness
1. Introduction
Nearly 20% of the general adult population in Japan has been reported to demonstrate
symptoms related to insomnia [1,2], and it is known that 5–19% of individuals have insomnia
that follows a chronic course [3,4]. In addition, insomnia severity has a great association with
depression severity and symptoms [5], and sleep disturbances increase the risk of sick leave up to
23% [6]. Currently, cognitive behavioral therapy (CBT-I) is recommended as a treatment for chronic
insomnia [4,7].
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There are several self-rating scales for insomnia severity currently available for evaluating
subjective insomnia. Among these, the Insomnia Severity Index (ISI) [8–10] and Athens Insomnia Scale
(AIS) [11–13] are commonly used as authorized insomnia symptom questionnaires. These scales have
been shown to have appropriate diagnostic utility, and they include a set of items for evaluating both
nocturnal sleep disturbance and daytime dysfunction. In particular, the ISI includes some psychological
components of insomnia (e.g., worry and satisfaction), while the AIS includes physiological components
(e.g., sleepiness and functioning capacity during the day). Chiu et al. [14] conducted a meta-analysis to
evaluate the diagnostic accuracy of three screening tools for insomnia: the ISI, AIS, and Pittsburgh
Sleep Quality Index (PSQI) [15]. They showed that these scales are useful instruments for insomnia
screening, and the diagnostic accuracy of each scale (sensitivity and specificity) was high (ISI: 88%
and 85%, AIS: 91% and 87%, and PSQI: 94% and 76%, respectively). In particular, they suggested that
the ISI and AIS are probably stronger and appropriate instruments than the PSQI, according to the
comparisons of scale characteristics for diagnostic properties, sleep domains, and feasibility [14].
With regard to the specific characteristics of each scale, the ISI is only capable of categorizing
insomnia severity as follows: absence of insomnia (0 to 7 points), subthreshold (mild) insomnia (8 to
14 points), moderate insomnia (15 to 21 points), and severe insomnia (22 points or more) [8]. Therefore,
the scale has been frequently utilized in clinical researches [4,7].
On the other hand, the AIS estimates nocturnal sleep disturbance and daytime dysfunctions that
occur at least three times a week, on the basis of the International Classification of Diseases, 10th edition
(ICD-10) criteria [11,12]. It was reported that the cutoff score is 5.5 points in both European and Asian
countries [11,13], which is a common score across cultures. However, the AIS was rarely used in clinical
studies [16] but frequently utilized in cohort or cross-sectional studies [17,18]. Furthermore, there is yet
to be a study examining the accuracy of insomnia severity in insomnia scales, although the diagnostic
accuracy of insomnia scales has been reported [14].
Thus, both AIS and ISI are considered the “gold standard” of insomnia scales and have high
diagnostic accuracy. The AIS has some physical components while the ISI contains some psychological
components. In addition, the AIS can be regarded as a highly useful instrument in both clinical and
research settings, except for not having the ability to assess severity level. Since the AIS created the
basis of the ICD-10 diagnostic criteria, more diverse findings can be found than ever before, not only
in cross-sectional and cohort studies, but also in clinical trials, if the AIS is capable of assessing the
severity of insomnia. Therefore, this study aimed to determine the severity criteria for AIS using ISI,
which categorizes mild, moderate, and severe levels of insomnia.
2. Materials and Methods
2.1. Participations
Participants were government employees of Koka city, which is a rural city in the Shiga Prefecture
of Japan [19]. Employees for whom the consent of a legal representative was required for participation
or who had taken extended leave from employment were excluded. Among the 2119 prefectural
government’s employments, 62 were excluded because of extended leave, including sick, maternity,
and childcare leave. Thus, a total of 2057 participants were included. Responses to the questionnaire
were obtained from 1685 people anonymously (response rate: 81.9%). Of them, 1666 people completely
answered both AIS and ISI (649 males, 1017 females, mean age (SD): 45.33 (12.20) years old).
The questionnaire survey was conducted from 6 September to 15 November 2017.
2.2. Measures
2.2.1. Insomnia Symptoms
Insomnia symptoms were measured using the Japanese version of AIS [13], a validated eight-item
self-report questionnaire that assesses insomnia symptom over the past month. A sum score is calculated
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(range: 0–24), with lower scores indicating fewer insomnia symptoms. A cutoff score discriminating
healthy patients from those suffering from insomnia is 5.5 points [12,13]. Insomnia severity was
measured using the Japanese version of ISI [10], a validated seven-item self-report questionnaire that
assesses insomnia severity over the past 2 weeks. A sum score is calculated (range: 0–28), with lower
scores indicating fewer insomnia symptoms. Severity level is categorized as no insomnia (0 to 7 points),
subthreshold (mild) insomnia (8 to 14 points), moderate insomnia (15 to 21 points), and severe insomnia
(22 points or more) [8].
2.2.2. Daytime Sleepiness, Depressive Symptoms, and Quality of Life (QoL)
We measured depressive symptoms, daytime sleepiness, and QoL as insomnia-related daytime
dysfunction. Depressive symptoms were measured using the Japanese version of Patient Health
Questionnaire (PHQ-9) [20], a validated nine-item questionnaire that assesses depressive symptom
severity over the past week. A sum score is calculated (range: 0–27), with lower scores indicating less
depression. Daytime sleepiness was measured using the Japanese version of Epworth Sleepiness Scale
(ESS) [21], a validated eight-item questionnaire that assesses excessive daytime sleepiness. A sum score
is calculated (rage: 0–24), with lower scores indicating less sleepiness. QoL was measured using the
Japanese version of Short Form Health Survey of the Medical Outcomes Study (SF-8) [22], a validated
eight-item questionnaire that assesses health-related quality of life over the past week. The mental
component summary (MCS) scale of the SF-8 was used to evaluate mental QoL, and the physical
component summary (PCS) scale was used to evaluate physical QoL. The average scores for both
scales for the general population were set to 50 points.
2.3. Procedures
A cross-sectional questionnaire-based study was conducted as part of the Night in Japan
Home Sleep Monitoring (NinJaSleep) Study, which is an epidemiological study on sleep and mental
health [19]. The study was approved by the ethics committee of the Shiga University of Medical
Science (27-056). Informed consent was obtained from each participant prior to participation.
We distributed a questionnaire at their workplace, and the individuals who responded to the
questionnaire remained anonymous.
2.4. Statistics Analysis
Descriptive statistics were computed using R statistical software version 3.6.3 (R Project for
Statistical Computing, Vienna, Austria). To associate between the AIS and ISI, we conducted a
correlation analysis and an exploratory factor analysis utilizing a maximum-likelihood solution method
with promax rotation. In the factor analysis, all items on the AIS and ISI were analyzed simultaneously.
Factors were determined by setting eigenvalues to ≥1 according to the shape of the scree plot.
In addition, we described a receiver–operator curve (ROC) in order to determine severity levels of
mild, moderate, and severe insomnia. The ROC was plotted, and the mean (95% confidence interval
(CI)) area under the curve (AUC) was used to estimate an AIS cutoff score for distinguishing pathological
insomnia from a normal condition. When the tangent line slope of the ROC is statistically equal to
1 (i.e., AUC = 0.5), then the ROC is considered inaccurate for prediction purposes. The predictive
ability of a variable was classified with reference to the AUC (outstanding >0.9, excellent = 0.8–0.9,
good = 0.7–0.8, acceptable = 0.6–0.7, poor = 0.5–0.6, or nondiscriminative = 0.5) [23]. The best cutoff
value for pathological insomnia was determined on the basis of sensitivity, specificity, positive likelihood
ratio (LR+), and negative likelihood ratio (LR−). In accordance with the authorized method, the cutoff
score was assessed as adequate when LR+ was 2.0 or higher and LR−was 0.5 or less [2,24].
It was already revealed that a cutoff score discriminating normal sleep from insomnia is 5.5 points
on the AIS [13]. Therefore, we described the ROC of mild vs. moderate level and that of moderate vs.
severe level.
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On the basis of severity level of the AIS or ISI, we categorized four groups as no, mild, moderate,
and severe insomnia groups. An ANOVA was used to compare groups on each scale. When main
effects in all analyses were shown, we performed Bonferroni–Holm correction for p-values and then
conducted post hoc analyses.
3. Results
3.1. Exploratory Factor Analysis of AIS and ISI
Table 1 summarizes the participant characteristics. The correlation analysis showed a significant
positive correlation (r) between the AIS and the ISI (r (95%CI) = 0.80 (0.78–0.82), p < 0.001). In addition,
exploratory factor analysis on all items of the AIS and ISI showed a two-factor structure, namely,
“nocturnal sleep” and “sleep quality and daytime function” (Table 2). The factor of “nocturnal sleep”
consisted of items for initial, middle, and terminal insomnia, and the factor of “sleep quality and daytime
function” included items such as sleep quality (AIS item 5), wellbeing (AIS item 6), satisfied/dissatisfied
with sleep pattern (ISI item 4), and sleep problem interference with daily functioning (ISI item 5).
Table 1. Demographic characteristics and descriptive statistics of all measures.
Variables Mean SD
Age 45.33 12.20
Gender Male: 39% Female: 61%
Body mass index (BMI) 22.55 3.79
Insomnia Severity Index (ISI) 7.00 4.39
Athens Insomnia Scale (AIS) 5.02 3.60
Epworth Sleepiness Scale (ESS) 7.84 4.55
Patient Health Questionnaire-9 (PHQ-9) 4.67 4.55
Physical component summary (PCS) 47.72 7.19
Mental component summary (MCS) 47.36 7.48
Table 2. Exploratory factor analysis for AIS and ISI.
Items Contents
Factor Loadings
Factor 1 Factor 2
Factor 1: Sleep quality and daytime function
AIS 4 Total sleep duration 0.84 −0.15
ISI 7 Worried/distressed about sleep pattern 0.79 0.05
ISI 4 Satisfied/dissatisfied with sleep pattern 0.79 −0.05
ISI 5 Sleep problem interference with daily functioning 0.78 −0.07
AIS 5 Sleep quality 0.66 0.19
ISI 6 Sleep problem noticeable to others 0.64 −0.03
AIS 8 Sleepiness during the day 0.60 −0.08
AIS 7 Functioning capacity during the day 0.54 0.11
AIS 6 Well-being during the day 0.52 0.14
Factor 2: Nocturnal sleep
ISI 2 Difficulty staying asleep −0.05 0.85
AIS 2 Awakenings during the night −0.03 0.82
ISI 3 Problem with waking too early −0.04 0.75
AIS 3 Final awakening −0.07 0.72
ISI 1 Difficulty falling asleep 0.11 0.51
AIS 1 Sleep induction 0.16 0.45
Factor correlation
Factor 1 1.00 −0.60
Factor 2 1.00
AIS, Athens Insomnia Scale; ISI, Insomnia Severity Index.
3.2. ROC to Evaluate Severity Level of the AIS
We used the ROC to examine the cutoff value of mild, moderate, and severe levels for the AIS
scores. As a result, the AUC of the ROC was 0.87 (95% CI, 0.83 to 0.90, p < 0.001) at a mild/moderate
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level and 0.94 (95% CI, 0.86 to 1.00, p < 0.001) at a moderate/severe level (Figure 1). Both values were
statistically larger than 0.50.
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Table 3. Cutoff scores of the AIS for insomnia.
Severity Level Cutoff Score Sensitivity Specificity LR+ LR−
Mild vs.
moderate 6.50 0.96 0.47 1.81 0.09
7.50 0.92 0.62 2.44 0.13
8.50 0.84 0.75 3.30 0.22
9.50 0.74 0.83 4.45 0.32
10.50 0.64 0.89 5.89 0.41
11.50 0.53 0.92 6.94 0.51
Moderate vs.
severe 12.50 1.00 0.62 2.61 0.00
13.50 0.88 0.76 3.61 0.17
14.50 0.88 0.89 7.88 0.14
15.50 0.88 0.91 9.63 0.14
16.50 0.63 0.95 12.38 0.40
17.50 0.63 0.97 20.63 0.39
AIS, Athens Insomnia Scale; LR+, positive likelihood ratio; LR−, negative likelihood ratio. Bold types indicate the
cutoff values identified in this study.
Therefore, the severity criteria of the AIS are capable of categorizing insomnia severity as
follows: absence of insomnia (0–5), mild insomnia (6–9), moderate insomnia (10–15), and severe
insomnia (16–24).
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3.3. Comparison of the Scales Based on the Cutoff for AIS or ISI
We categorized insomnia into four groups, absence of insomnia, mild insomnia, moderate insomnia,
and severe insomnia, on the basis of the cutoff values for the AIS or ISI. It was revealed that similar
results could be obtained using either criteria (Figures 2 and 3). The scores for insomnia symptoms
(i.e., ISI or AIS) and PHQ-9 were significantly higher in the order of severe, moderate, mild, and absence
of insomnia (ISI cutoff: AIS (F3,1665 = 581.84, p < 0.001), PHQ-9 (F3,1664 = 275.40, p < 0.001); AIS cutoff:
ISI (F3,1665 = 648.62, p < 0.001); PHQ-9 (F3,1664 = 423.28, p < 0.001)). The scores of ESS were higher
for moderate and severe insomnia than for mild insomnia and absence of insomnia (ISI cutoff:
F3,1665 = 43.86, p < 0.001; AIS cutoff: F3,1665 = 49.08, p < 0.001). The scores of PCS and MCS of
SF-8 were lower in the order of severe, moderate, mild, and absence of insomnia (ISI cutoff: PCS
(F3,1654 = 52.03, p < 0.001); MCS (F3,1654 = 93.66, p < 0.001); AIS cutoff: PCS (F3,1654 = 68.77, p < 0.001);
MCS (F3,1654 = 190.43, p < 0.001)).
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4. Discussion
This study aimed to determine the severity criteria for AIS using ISI, which categorizes mild,
moderate, and severe levels of insomnia. It showed that the severity criteria of the AIS were
capable of categorizing insomnia severity as follows: absence of insomnia (0–5), mild insomnia (6–9),
moderate insomnia (10–15), and severe insomnia (16–24).
The result of correlational analysis revealed that the AIS was strongly associated with the ISI.
This finding is consistent with a previous study (r = 0.85) [13]. In addition, as a result of simultaneous
exploratory factor analysis of all items on the AIS and ISI, it was found that nocturnal sleep disturbances
and daytime sleep dysfunction were distinguished. Chronic insomnia disorder is defined as nocturnal
sleep disturbances (difficulty initiating sleep, difficulty maintaining sleep, and waking up earlier than
desired) and results in some form of daytime dysfunction [25]. Therefore, the findings of the two-factor
structure are plausible, and it is thought that the AIS and ISI comprise almost the same construct.
The severity level of insomnia was identified using an ROC. In previous studies, some cutoff
points of the AIS were shown as follows: ≥6 points (insomniac vs. non-insomniac group) [12,13],
≥7 points (insomniac vs. non-insomniac group) [9,26] and ≥10 points (insomniac vs. psychiatric
patients) [12]. However, these points are a screening criterion for insomnia and do not reflect the
severity of insomnia. From the results of the AUC, sensitivity, specificity, LR+, and LR−, the severity
criteria of AIS could be extremely useful. Meanwhile, the sensitivity of the cutoff value between
mild and moderate levels was relatively low. Since this study was based on a community sample,
the validity of the cutoff value requires examination in patient samples in future research.
Furthermore, the results of ANOVAs using the severity categories of AIS or ISI were similar
for changes in daytime sleepiness, depression, and health-related QoL. This is remarkable because
there are no studies showing that daytime functioning declines with increasing insomnia severity.
In randomized clinical trials, the severity level of insomnia (e.g., ISI≥ 8) was used as one of the inclusion
criteria of the trial [27,28] and as a remission and response criterion [29]. Nonetheless, our study is the
only epidemiological study that examined the severity of insomnia, although it was shown that the
prevalence of insomnia worsens daytime function such as depression and health-related QoL [19,30],
and that insomnia impaired daytime function compared with good sleep [31].
This finding allows not only to examine the prevalence of insomnia in the community sample but
also the prevalence, natural history, or association with daytime functions as a function of the severity
of insomnia. The identification of severity of AIS in this study is important in linking the findings of
epidemiological studies with those of clinical studies.
This study had some limitations. First, our participants were city government employees in Japan.
Therefore, it is unclear whether they may have been representative of the general Japanese population.
Second, we used cross-sectional data and, hence, we cannot provide information on the causality of
the observed associations. It is necessary to plan to conduct a cohort study in this population or the
general Japanese population in future research.
5. Conclusions
In conclusion, the results of this study showed that the AIS can be used to grade the severity of
insomnia. Therefore, cross-sectional and cohort studies on the impact of insomnia on social and mental
function can be studied in detail. In addition, the AIS can be used in clinical studies in future research.
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